Clinical Trial Update: Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab [Phase 4]

View source ↗

Summary

Phase 4 study evaluating abrocitinib in adults with atopic dermatitis who did not adequately respond to dupilumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)
• Dupilumab (dupilumab)

Snippet

Sponsor: Innovaderm Research Inc. | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED